Pasi A. Jänne

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

4.0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Nature Genetics(2023)10.1038/s41588-023-01355-5

Top 6%

4.0DataRank

Top 6%188 citations

Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai +37 more

Papers

Driven by 69 papers — median percentile 0. Top paper: “Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer”.

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

Nature Genetics(2023)10.1038/s41588-023-01355-5

Top 6%

4.0DataRank

Top 6%188 citations

Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai +37 more

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

The Lancet Oncology(2024)10.1016/s1470-2045(24)00064-0

N/A

3.7DataRank · unranked

164 citations

Enriqueta Felip, Dipesh Uprety, Misako Nagasaka, Kazuhiko Nakagawa, Luis Paz‐Ares +15 more

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0217

N/A

3.2DataRank · unranked

126 citations

Nataliya V. Uboha, Meredith S. Pelster, Tanios Bekaii‐Saab, Minal Barve, Joel Saltzman +12 more

MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer

Cancer Cell(2022)10.1016/j.ccell.2022.08.015

N/A

2.6DataRank · unranked

102 citations

Tetsuo Tani, Benjamin F. Springer, Marco Campisi, Tatsuya Osaki, Koji Haratani +23 more

Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

Nature Communications(2022)10.1038/s41467-022-30258-y

N/A

2.0DataRank · unranked

88 citations

Ciric To, David E. Heppner, Jaimin K. Rana, Anna M. Schmoker, Jaebong Jang +7 more

Activation of Tumor-Cell STING Primes NK-Cell Therapy

Cancer Immunology Research(2022)10.1158/2326-6066.cir-22-0017

N/A

1.8DataRank · unranked

90 citations

Elena V. Ivanova, Mubin Tarannum, Marco Campisi, Patrick H. Lizotte, Matthew A. Booker +44 more

Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9507

N/A

1.5DataRank · unranked

39 citations

Daniel B. Costa, Cloud P. Paweletz, Mark M. Awad, Paul Marcoux, Deepa Rangachari +13 more

Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis

JCO Precision Oncology(2020)10.1200/po.20.00121

N/A

1.5DataRank · unranked

29 citations

Evan W. Clark, Marina S.D. Milan, Christine Champagne, Kesi Michael, Mark M. Awad +10 more

Germline EGFR Mutations and Familial Lung Cancer

Journal of Clinical Oncology(2023)10.1200/jco.23.01372

N/A

1.4DataRank · unranked

60 citations

Ruthia Chen, Jennifer C. Pharr, Diane R. Koeller, Arrien A. Bertram, Suzanne E. Dahlberg +18 more

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Science(2004)10.1126/science.1099314

N/A

1.4DataRank · unranked

9384 citations

Pasi A. Jänne, Jeffrey C. Lee, Sean Tracy, Heidi Greulich, Anthony Philippakis +13 more

Design of a “Two-in-One” Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites

Journal of Medicinal Chemistry(2021)10.1021/acs.jmedchem.1c00848

N/A

1.3DataRank · unranked

45 citations

David E. Heppner, Ciric To, Marcel Günther, Bo Hee Shin, Jaimin K. Rana +13 more

The landscape of somatic copy-number alteration across human cancers

Nature(2010)10.1038/nature08822

N/A

1.2DataRank · unranked

4101 citations

Craig H. Mermel, Dale A. Porter, Guo Wei, Soumya Raychaudhuri, Jerry Donovan +61 more

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

Cancer Cell(2020)10.1016/j.ccell.2019.12.006

N/A

0.925DataRank · unranked

477 citations

Yao Liu, Ciric To, Tinghu Zhang, Mengyang Fan, Amir Vajdi +39 more

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

Cancer Discovery(2020)10.1158/2159-8290.cd-19-1014

N/A

0.882DataRank · unranked

357 citations

Hiroji Iwata, Ian E. Krop, Pasi A. Jänne, Toshihiko Doi, Shunji Takahashi +11 more

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

UNC Libraries(2021)10.17615/d9z4-0943

N/A

0.881DataRank · unranked

26 citations

Chun-Xiao Xu, Michael D. Cameron, D. Neil Hayes, Lucian R. Chirieac, Jing Ouyang +38 more

ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1

Molecular Cell(2022)10.1016/j.molcel.2022.04.034

N/A

0.841DataRank · unranked

23 citations

Radha Mukherjee, Rona Yaeger, Jieun Son, Jianing Xu, Na Na +22 more

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3608

N/A

0.811DataRank · unranked

222 citations

Magda Bahcall, Liam F. Spurr, Jianwei Che, Biagio Ricciuti, Giulia C. Leonardi +18 more

Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity

Cancer Discovery(2021)10.1158/2159-8290.cd-20-0913

N/A

0.809DataRank · unranked

219 citations

Erik H. Knelson, Jacquelyn O. Wolff, Amir Vajdi, Maria Saigí, Marco Campisi +38 more

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.02.011

N/A

0.764DataRank · unranked

162 citations

Emily S. Chambers, Tom Nguyen, Alexis Coolidge, Christine Lydon, Xiuning Le +6 more

Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3305

N/A

0.725DataRank · unranked

125 citations

Pasi A. Jänne, Mateusz Opyrchal, Navid Hafez, Luis E. Raez, Dmitry I. Gabrilovich +15 more

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2278

N/A

0.724DataRank · unranked

124 citations

Melissa L. Johnson, Sarah Clifford, Romel Somwar, Jennifer Kherani, Jieun Son +23 more

Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer

Cancer Cell(2023)10.1016/j.ccell.2023.07.005

N/A

0.710DataRank · unranked

113 citations

Claudia Gentile, William W. Feng, Shannon J. Silva, Akshay Sankar, Francisco Expósito +21 more

FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma

Cancer Discovery(2021)10.1158/2159-8290.cd-20-1669

N/A

0.705DataRank · unranked

109 citations

Srivatsan Raghavan, Qibiao Wu, Yvonne Y. Li, Liam F. Spurr, Hersh Gupta +35 more

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.07.005

N/A

0.701DataRank · unranked

106 citations

Joao V. Alessi, Arielle Elkrief, Xinan Wang, Alessio Cortellini, Y Y Li +27 more

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-4084

N/A

0.574DataRank · unranked

45 citations

Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura +15 more

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-1844

N/A

0.564DataRank · unranked

42 citations

Mari Kuraguchi, Man Xu, Andrew Portell, Luke J. Taus, Irmina Diala +17 more

MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer

Cancer Research(2022)10.1158/0008-5472.can-22-0770

N/A

0.553DataRank · unranked

39 citations

Maria Saigí, Tetsuo Tani, Benjamin F. Springer, Hirofumi Shibata, Shunsuke Kitajima +19 more

A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non–Small Cell Lung Cancer

Cancer Research(2022)10.1158/0008-5472.can-21-2693

N/A

0.546DataRank · unranked

37 citations

Jaebong Jang, Tyler S. Beyett, Yoonji Eum, Heidi M. Haikala, Alyssa Verano +13 more

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

UNC Libraries(2021)10.17615/6prg-vp52

N/A

0.546DataRank · unranked

37 citations

Hongbin Ji, Norman E. Sharpless, Pasi A. Jänne, Mitchell Albert, Daniel G. Tenen +16 more

ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps9077

N/A

0.520DataRank · unranked

31 citations

Sumithra J. Mandrekar, Geoffrey R. Oxnard, David Kozono, Shauna L. Hillman, Suzanne E. Dahlberg +13 more

Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC

JCO Precision Oncology(2021)10.1200/po.20.00419

N/A

0.510DataRank · unranked

29 citations

Christie J. Lau, Marina S.D. Milan, Julianna Supplee, Jonathan W. Riess, Penelope A. Bradbury +4 more

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma

Annals of Oncology(2023)10.1016/j.annonc.2023.04.514

N/A

0.510DataRank · unranked

29 citations

Christine Lydon, Emily S. Chambers, Lynette M. Sholl, Mizuki Nishino, Ferdinandos Skoulidis +8 more

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors

Nature Communications(2022)10.1038/s41467-022-33210-2

N/A

0.505DataRank · unranked

28 citations

Geoffrey R. Oxnard, Elizabeth F. Cohen, Navin R. Mahadevan, Joao V. Alessi, Yin P. Hung +18 more

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors

Annals of Oncology(2024)10.1016/j.annonc.2024.11.014

N/A

0.489DataRank · unranked

25 citations

Lingzhi Hong, Arielle Elkrief, Rohit Thummalapalli, Alissa J. Cooper, Biagio Ricciuti +43 more

Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.12.019

N/A

0.489DataRank · unranked

25 citations

Maisam Makarem, Mizuki Nishino, S. Emily Bachert, Tom Zhang, Jaclyn LoPiccolo +11 more

Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0795

N/A

0.477DataRank · unranked

23 citations

Grace A. Heavey, Yanan Kuang, Emily Durlacher, Thian Kheoh, Richard C. Chao +10 more

Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer

UNC Libraries(2020)10.17615/ge7q-0q17

N/A

0.442DataRank · unranked

18 citations

Sean T. Bailey, David J. Kwiatkowski, Pasi A. Jänne, Jeffrey A. Engelman, Julián Carretero +35 more

Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.12.022

N/A

0.416DataRank · unranked

15 citations

Michelle Sanchez, Elinton Lee, Hans J. Hertzler, Nhi M. Luong, Emanuele Mazzola +17 more

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9014

N/A

0.373DataRank · unranked

11 citations

Mark Krailo, Sukhmani K. Padda, Susan Groshen, Heather A. Wakelee, Karen L. Reckamp +14 more

First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1735

N/A

0.345DataRank · unranked

9 citations

Hui Li, Alessandro Di Federico, Jia Wu, Hong Chen, Eleonora Gariazzo +26 more

Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.03.045

N/A

0.292DataRank · unranked

6 citations

Federica Pecci, Biagio Ricciuti, Felix H. Gottlieb, Francesco Facchinetti, Guilherme Harada +21 more

ZNL0325, a Pyrazolopyrimidine-Based Covalent Probe, Demonstrates an Alternative Binding Mode for Kinases

Journal of Medicinal Chemistry(2024)10.1021/acs.jmedchem.3c01891

N/A

0.241DataRank · unranked

4 citations

Wenchao Lu, Tyler S. Beyett, Scott B. Ficarro, Jie Jiang, Jason Tse +8 more

Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3747

N/A

0.208DataRank · unranked

3 citations

Alison M. Urvalek, Minh Ha, Kavita S. Garg, Aimee Bence Lin, Anna M. Szpurka +4 more

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies

Clinical Lung Cancer(2025)10.1016/j.cllc.2025.09.009

N/A

0.104DataRank · unranked

1 citations

Leena Gandhi, Vignesh Ravichandran, Benjamin Besse, Julien Mazières, Geoffrey I. Shapiro +20 more

Development of Mutant-Selective Allosteric EGFR Inhibitors for Drug-Resistant Lung Cancer

Journal of Pharmacology and Experimental Therapeutics(2023)10.1124/jpet.122.162040

N/A

0DataRank · unranked

1 citations

Ciric To, David E. Heppner, Thomas W. Gero, Nathanael S. Gray, David A. Scott +3 more

A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology

Molecular Pharmacology(2023)10.1124/molpharm.123.000768

N/A

0DataRank · unranked

2 citations

Ilse K. Schaeffner, David E. Heppner, Ciric To, Pasi A. Jänne, Tyler S. Beyett +2 more

Data from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

(2023)10.1158/0008-5472.c.6495762

N/A

0DataRank · unranked

0 citations

Zhenxiong Wang, Samanthi A. Perera, Danan Li, Mei‐Chih Liang, Sara Zaghlul +15 more

Data from Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis

(2023)10.1158/0008-5472.c.6493908

Top 100%

0DataRank

Top 100%0 citations

Barbara A. Weir, Thomas LaFramboise, Ming Lin, Rameen Beroukhim, Levi A. Garraway +15 more

Data from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

(2023)10.1158/0008-5472.c.6495762.v1

N/A

0DataRank · unranked

0 citations

Zhenxiong Wang, Samanthi A. Perera, Danan Li, Mei‐Chih Liang, Sara Zaghlul +15 more

Data from Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis

(2023)10.1158/0008-5472.c.6493908.v1

Top 100%

0DataRank

Top 100%0 citations

Barbara A. Weir, Thomas LaFramboise, Ming Lin, Rameen Beroukhim, Levi A. Garraway +15 more

Data from MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer

(2023)10.1158/0008-5472.c.6514215.v1

N/A

0DataRank · unranked

0 citations

Maria Saigí, Tetsuo Tani, Benjamin F. Springer, Hirofumi Shibata, Shunsuke Kitajima +19 more

Data from MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer

(2023)10.1158/0008-5472.c.6514215

N/A

0DataRank · unranked

0 citations

Maria Saigí, Tetsuo Tani, Benjamin F. Springer, Hirofumi Shibata, Shunsuke Kitajima +19 more

Data from A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

(2023)10.1158/1078-0432.c.6518359.v1

N/A

0DataRank · unranked

0 citations

Lucian R. Chirieac, Kenny Law, Jason L. Hornick, Neal I. Lindeman, Eugene J. Mark +6 more

Data from Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

(2023)10.1158/1078-0432.c.6520385.v1

N/A

0DataRank · unranked

0 citations

David S. Boss, D. Ross Camidge, Carolyn D. Britten, Jeffrey A. Engelman, Edward B. Garon +9 more

Data from Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

(2023)10.1158/1078-0432.c.6520385

N/A

0DataRank · unranked

0 citations

David S. Boss, D. Ross Camidge, Carolyn D. Britten, Jeffrey A. Engelman, Edward B. Garon +9 more

Data from A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing

(2023)10.1158/2326-6066.c.6549088.v1

N/A

0DataRank · unranked

0 citations

Ruey‐Long Hong, Troy A. Luster, Megan E. Cavanaugh, Luke J. Taus, Stephen Wang +14 more

2294P Whole genome sequencing to define the germline-somatic interaction in young-onset lung cancer

Annals of Oncology(2023)10.1016/j.annonc.2023.09.1321

N/A

0DataRank · unranked

0 citations

Rory Collins, Diane R. Koeller, Alicia Pollaci, E. Voligny, Tom Nguyen +9 more

Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations

Angewandte Chemie(2020)10.1002/ange.202003500

N/A

0DataRank · unranked

15 citations

Ciric To, Dries J.H. De Clercq, Eunyoung Park, Charles M. Ponthier, Bo Hee Shin +7 more

Transferrin receptor targeting chimeras for membrane protein degradation

Nature(2024)10.1038/s41586-024-07947-3

N/A

0DataRank · unranked

156 citations

Jhoely Duque-Jimenez, Francesco Facchinetti, Garyk Brixi, Kaitlin Rhee, William W. Feng +3 more

Molecular Design of a “Two-in-One” Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor

ChemRxiv(2020)10.26434/chemrxiv.13416452

N/A

0DataRank · unranked

1 citations

david heppner, Ciric To, Marcel C. Guenther, Bo Hee Shin, Jaimin K Rana +6 more

Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations

Angewandte Chemie International Edition(2020)10.1002/anie.202003500

N/A

0DataRank · unranked

140 citations

Ciric To, Dries J.H. De Clercq, Eunyoung Park, Charles M. Ponthier, Bo Hee Shin +7 more

Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality

ACS Central Science(2024)10.1021/acscentsci.3c01245

N/A

0DataRank · unranked

15 citations

Jie Jiang, Scott B. Ficarro, Tyler S. Beyett, Ciric To, Isidoro Tavares +9 more

Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2417144121

N/A

0DataRank · unranked

5 citations

Tyler S. Beyett, Jie Jiang, Jaimin K. Rana, Ilse K. Schaeffner, J. A. da S. Santana +3 more

Molecular Design of a “Two-in-One” Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor

(2020)10.26434/chemrxiv.13416452.v1

N/A

0DataRank · unranked

0 citations

David E. Heppner, Ciric To, Marcel C. Guenther, Bo Hee Shin, Jaimin K Rana +6 more

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

UNC Libraries(2020)10.17615/j6a6-ag16

N/A

0DataRank · unranked

0 citations

Jacob B. Reibel, Jeremy H. Tchaicha, Julián Carretero, Pasi A. Jänne, Mohit Butaney +22 more

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer

Nature Cancer(2022)10.1038/s43018-022-00351-8

N/A

0DataRank · unranked

163 citations

Tyler S. Beyett, Jaebong Jang, William W. Feng, Magda Bahcall, Heidi M. Haikala +21 more

Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19

Journal of Medicinal Chemistry(2022)10.1021/acs.jmedchem.2c01041

N/A

0DataRank · unranked

31 citations

Tyler S. Beyett, William W. Feng, Andreas Krämer, Janik Weckesser, Ilse K. Schaeffner +6 more

RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.64898/2025.12.15.693503

N/A

0DataRank · unranked

1 citations

Jie Jiang, Javier Vinals Camallonga, Dimitris Gazgalis, Thomas W. Gero, Maurício T. Tavares +13 more

Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC

Bioorganic & Medicinal Chemistry Letters(2022)10.1016/j.bmcl.2022.128718

N/A

0DataRank · unranked

23 citations

David E. Heppner, Tyler S. Beyett, Ciric To, Seth C. Azevedo, Jaebong Jang +11 more

Pasi A. Jänne

Indexed papers

Top data-sharing exemplar

Papers